MBBS (Singapore) – M.Med (Singapore) – MRCP (United Kingdom), FAMS (Medical Oncology)
Dr Tan Sing Huang is a Senior Consultant Medical Oncologist with OncoCare Cancer Centre. Prior to entering private practice, she held the position of Senior Consultant in the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS). She was also leading the Senior Residency Education division in NCIS as its Program Director since 2012 and successfully led the department in obtaining its initial American College of Graduate Medical Education-International (ACGME-I) accreditation in 2013 and once again its re-accreditation in 2015. She was also Co-Chairman for the NCIS Clinical Competency Committee for the Senior Residency training and also previously panel member for National Interviews for selection of Medical Oncology trainees since 2014. She also contributed to undergraduate education as an Assistant Professor of the Yong Loo Lin School of Medicine, National University of Singapore and participated as an examiner for undergraduate final medical exams. As a result of her contributions to Education in the National University Hospital (NUH), she was awarded the NUH Teaching Excellence Award in 2014. Given her interest in continuing medical education, she has also helped to organize and served as Chairman of conferences such as the Best of ASCO in 2015 and co-organised the inaugural Breast Day Symposium in 2016.
During her work at the National University Hospital Medical Oncology division since 2001, she had continued to take care of patients with a wide variety of cancers, including Breast cancers, Gynecological cancers, Lung cancers and Gastrointestinal cancers, although her primary interest is in Women’s Cancers. She was also involved in clinical drug trials by being the principal investigator of several multi-center studies investigating new investigational drugs in HER2-positive breast cancers as well as being co-investigator of several multi-centre clinical trials in lung, colorectal and breast cancers.
She went overseas to complete a postgraduate research fellowship at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Centre in Baltimore in 2006-2007 where she was involved in epigenetics research and also gained clinical experience from attachments with the Breast Cancer Division of Johns Hopkins Medical Institute. Upon her return to Singapore, she was awarded the Research-Investigator-Scientist Enabler (RISE) Grant Scheme Award from 2008 to 2010, and also the Junior Investigator Protected Time Award in 2011.
She has also been involved in many research publications in international journals including those on the use of neoadjuvant doxorubicin and cyclophosphamide with or without sunitinib in breast cancer, pharmacogenetics-guided use of capecitabine in patients with advanced or metastatic tumours, dose modifications in Asian cancer patients receiving weekly docetaxel, and genotyping of human carbonyl reductase CBR3 with doxorubicin disposition and toxicity. These publications have appeared in several journals including Clinical Cancer Research and Annals of Oncology. She has also given many local and overseas talks as an invited speaker.
Dr Tan is co-chair of the BreastDay Meeting and she will be giving a talk on "Systemic Treatment - Updates from ASCO" at BreastDay.